Parametry
- 352 strony
- 13 godzin czytania
Więcej o książce
"In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Zakup książki
Bad Blood, John Carreyrou
- Język
- Rok wydania
- 2018
- Oprawa
- (miękka)
Metody płatności
Brakuje nam tutaj Twojej recenzji.
- Tytuł
- Bad Blood
- Język
- angielski
- Autorzy
- John Carreyrou
- Wydawca
- Alfred A. Knopf
- Rok wydania
- 2018
- Oprawa
- miękka
- Liczba stron
- 352
- ISBN10
- 1524711489
- ISBN13
- 9781524711481
- Seria
- Pierwsze wydanie
- 2018
- Oryginalna nazwa
- Bad Blood: Secrets and Lies in a Silicon Valley Startup
- Ocena
- 4,45 z 5
- Opis
- "In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--